Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jun;136(3):391-8.
doi: 10.1038/sj.bjp.0704725.

Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness

Affiliations

Increased arginase activity underlies allergen-induced deficiency of cNOS-derived nitric oxide and airway hyperresponsiveness

Herman Meurs et al. Br J Pharmacol. 2002 Jun.

Abstract

1. A deficiency of constitutive nitric oxide synthase (cNOS)-derived nitric oxide (NO), due to reduced availability of L-arginine, importantly contributes to allergen-induced airway hyperresponsiveness (AHR) after the early asthmatic reaction (EAR). Since cNOS and arginase use L-arginine as a common substrate, we hypothesized that increased arginase activity is involved in the allergen-induced NO deficiency and AHR. 2. Using a guinea-pig model of allergic asthma, we addressed this hypothesis by examining the effects of the specific arginase inhibitor N(omega)-hydroxy-nor-L-arginine (nor-NOHA) on the responsiveness to methacholine of isolated perfused tracheae from unchallenged control animals and from animals 6 h after ovalbumin challenge. Arginase activity in these preparations was investigated by measuring the conversion of L-[14C]arginine to [14C]urea. 3. Airways from allergen-challenged animals showed a 2 fold (P<0.001) increase in responsiveness to intraluminal (IL) administration of methacholine compared to controls. A similar hyperresponsiveness (1.8 fold, P<0.01) was observed in control airways incubated with the NOS inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME, 0.1 mM, IL), while L-NAME had no further effect on the airways from challenged animals. 4. Remarkably, 5 microM nor-NOHA (IL) normalized the hyperresponsiveness of challenged airways to basal control (P<0.001), and this effect was fully reversed again by 0.1 mM L-NAME (P<0.05). Moreover, arginase activity in homogenates of the hyperresponsive airways was 3.5 fold (P<0.001) enhanced compared to controls. 5. The results indicate that enhanced arginase activity contributes to allergen-induced deficiency of cNOS-derived NO and AHR after the EAR, presumably by competition with cNOS for the common substrate, L-arginine. This is the first demonstration that arginase is involved in the pathophysiology of asthma.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Methacholine (MeCh; IL)-induced constriction of intact perfused tracheal preparations obtained from (a) unchallenged guinea-pigs, in the absence (control) and presence of 0.1 mM L-NAME, 5.0 μM nor-NOHA, and 5.0 μM nor-NOHA plus 0.1, 0.5 or 1.0 mM L-NAME, and (b) ovalbumin (OA)-challenged guinea-pigs, in the absence (control) and presence of 5.0 and 10.0 μM nor-NOHA, 0.1 mM L-NAME, and 5.0 μM nor-NOHA plus 0.1 mM L-NAME. For comparison, methacholine-induced constriction of control preparations from unchallenged guinea-pigs is also shown in b. Methacholine, nor-NOHA and L-NAME were all applied to the IL compartment. Results are means±s.e.mean of 3 – 14 experiments.
Figure 2
Figure 2
Arginase activity in tracheal homogenates from unchallenged and ovalbumin (OA)-challenged guinea-pigs, in the absence (control) and presence of 0.1 mM L-NAME and 5.0 μM nor-NOHA. Results are means±s.e.mean of 3 – 7 experiments. *P<0.001, †P<0.0001 compared to unchallenged control; ‡P<0.005 compared to OA-challenged control.

References

    1. ASANO K., CHEE C.B., GASTON B., LILLY C.M., GERARD C., DRAZEN J.M., STAMLER J.S. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 1994;91:10089–10093. - PMC - PubMed
    1. BAGGIO R., EMIG F.A., CHRISTIANSON D.W., ASH D.E., CHAKDER S., RATTAN S. Biochemical and functional pr ofile of a newly developed potent and isozyme-selective arginase inhibitor. J. Pharmacol. Exp. Ther. 1999;290:1409–1416. - PubMed
    1. BARNES P.J.Nitric Oxide Asthma: Basic Mechanisms and Clinical Management 1998London: Academic Press Limited; 369–388.ed. Barnes, P.J., Rodger, I.W. & Thomson, N.C. pp
    1. BARNES P.J., BELVISI M.G. Nitric oxide and lung disease. Thorax. 1993;48:1034–1043. - PMC - PubMed
    1. BOOIJ-NOORD H., ORIE N.G., DE VRIES K. Immediate and late bronchial obstructive reactions to inhalation of house dust and protective effects of disodium cromoglycate and prednisolone. J. Allergy Clin. Immunol. 1971;48:344–354. - PubMed

Publication types

MeSH terms

LinkOut - more resources